Apnimed was built upon a simple idea – patients with Obstructive Sleep Apnea (OSA) need a safe and effective medication that addresses the underlying biology of the disease.
OSA is a serious disorder in which the upper airway partly or completely closes during sleep. The temporary suspension of breathing dramatically reduces blood oxygen levels, partially awakens the patient throughout the night, and mechanically and chemically stresses the entire body. Immediate consequences include excessive daytime sleepiness, fatigue, difficulty concentrating, depression, irritability, and sexual dysfunction. Long term consequences can be life-threatening, including treatment-resistant hypertension, atrial fibrillation, heart failure and strokes.
Our proprietary approach recognizes that OSA is largely a neurological disease, and our lead therapies are designed to target, with simple orally dosed medicines, the key underlying neurobiological mechanisms that lead to airway obstruction.
Born out of groundbreaking research conducted at Brigham and Women’s Hospital in Boston, our development candidates have the potential to be the first disease-modifying oral therapeutic for OSA, representing a dramatic shift in the way we treat this devastating disease.